Drug Development Services
We have offered high-quality non clinical drug development services for over 30 years to clients in the pharmaceutical, biotechnology, and chemical industries. Our integrated capabilities include drug metabolism and pharmacokinetics (DMPK), toxicology, bioanalytical services, and analytical and formulation development services. The goal of our nonclinical studies is to help determine which compounds have the greatest probability of success, and to build a solid scientific foundation for further development. We provide timely, accurate, and accessible data as well as scientific consulting to optimize the progress of your compound. Our experienced scientists offer standard and customized study designs as well as issue-driven research capabilities.
Focus Areas
- Drug Metabolism and Pharmacokinetics (DMPK)
Comprehensive selection of in vivo and in vitro DMPK services; standard regulatory-driven study designs and innovative approaches to unique drug development issues - Toxicology
Development of appropriate biological models to safety test client compounds; standard preclinical studies to evaluate the safety of new drug candidates; specialty studies with unique biological models to assess drug efficacy and ensure quick and efficient IND submission - Bioanalytical Chemistry Services
Support and consultation to major pharmaceutical companies; metabolite identification; clinical trial sample analysis; LC/MS methods development and validation; cGMP release of finished products; DMPK and toxicology support - Analytical and Formulation Development Services
Analytical support, contract formulation development, and consultation to pharmaceutical, chemical, and biotechnology companies; thermal analysis, solubility, structure, stability, moisture content, particle morphology, and other studies
Principal Investigators
Related Research
rti.orgRelated Content
UMBI President Jennie Hunter-Cevera to Join RTI International as Executive Vice President of Discovery and Analytical Sciences, Corporate Development
Jennie Hunter-Cevera, Ph.D., a distinguished scientist, business leader and the current president and CEO of the University of Maryland Biotechnology Institute (UMBI), will join RTI International July 1, as Executive Vice President of Discovery and Analytical Sciences and Corporate Development.